Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid

Rie Matsushima-Nishiwaki1, Masataka Okuno1,4, Yukihiko Takano1, Soichi Kojima2, Scott L. Friedman3 and Hisataka Moriwaki1

1 First Department of Internal Medicine, Gifu University School of Medicine, Gifu, Japan
2 Molecular Cellular Pathology Research Unit, RIKEN, Wako, Japan
3 Division of Liver Diseases, Mount Sinai School of Medicine, New York, USA

4 To whom correspondence should be addressed Email: mokuno{at}cc.gifu-u.ac.jp


    Abstract
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
We have reported previously that acyclic retinoid, a synthetic retinoid X receptor {alpha} (RXR{alpha})-ligand, suppresses the development of hepatocellular carcinoma (HCC) in patients with chronic liver disease. On the other hand, HCCs become refractory to physiological concentrations of the natural RXR{alpha}-ligand, 9-cis retinoic acid (9cRA), due to extracellular signal-regulated kinase (Erk) 1/2-mediated phosphorylation and inactivation of RXR{alpha}. Here, we show that acyclic retinoid restores the function of RXR{alpha} in human HCC-derived HuH7 cells by inactivating the Ras-Erk 1/2 signaling system, thereby dephosphorylating RXR{alpha}. In contrast, 9cRA failed to suppress phosphoErk 1/2 levels and subsequent RXR{alpha} phosphorylation. Although 9cRA also suppressed Ras activity, it simultaneously down-regulated mitogen-activated protein kinase phosphatase-1, an enzyme that inactivates Erk, thereby leaving the phosphorylation status of Erk unchanged. A combination of 9cRA (a potent ligand) and acyclic retinoid (a weak ligand preventing phosphorylation) resulted in a marked cooperation in transactivation via the RXR-response element and in inhibiting the proliferation of HuH7 cells. These events provide a novel molecular basis for the antitumor activity of acyclic retinoid against HCC.

Abbreviations: 4HPR, 4-hydroxyphenyl retinamide; 9cRA, 9-cis RA, retinoic acid; atRA, all-transRA; CRBP, cellular retinol-binding protein; EGF, epidermal growth factor; Erk, extracellular signal-regulated kinase; FCS, fetal calf serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HCC, hepatocellular carcinoma; MAP kinase, mitogen-activated protein kinase; MKP-1, MAP kinase phosphatase-1; RAR, retinoic acid receptor; RXR, retinoid X receptor; RXRE, RXR-response element; TGF-{alpha}, transforming growth factor-{alpha}; VDR, vitamin D receptor


    Introduction
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
Retinoids are prime candidates for cancer chemoprevention, as they have profound effects on cell growth, apoptosis and differentiation (1). In fact, experimental studies have revealed potent roles of retinoids in reversing the carcinogenesis process and suppressing malignant transformation (2). Loss of retinoid activity or responsiveness is closely linked to carcinogenesis in several organs including hepatocellular carcinoma (HCC) (3). We documented previously a local depletion of retinoid in human HCC tissues due to its rapid conversion to an inactive metabolite (3) and further showed in experimental and clinical studies that supplementation with a synthetic retinoid analogue, acyclic retinoid, suppresses the development of HCC (4,5). However, the molecular mechanism(s) underlying this effect has been unclear.

Retinoids exert their biological activities primarily through retinoic acid receptor (RAR) and retinoid X receptor (RXR), two members of the nuclear receptor superfamily that act as ligand-dependent transcriptional regulators (6). RAR interacts with both all-trans retinoic acid (atRA) and 9-cis RA (9cRA), whereas RXR binds only to 9cRA. Acyclic retinoid is a ligand of both RAR and RXR (7). Both RAR and RXR consist of three subtypes, -{alpha}, -ß and -{gamma}, characterized by a modular domain structure. RXR forms a homodimer as well as heterodimers with RAR and other nuclear receptors, including vitamin D receptor (VDR), thyroid hormone receptor and peroxisome proliferator-activated receptor (PPAR), and thereby participates in the regulation of respective downstream genes. Among three subtypes of RXR, RXR{alpha} is highly expressed in human HCC and HCC-derived HuH7 cells (8). These dimers bind to their respective response elements and subsequently activate or inhibit the expression of target genes. Transcriptional activity of retinoid receptors is regulated by several factors that modulate the composition of their receptor complexes (7). In the absence of RA, unliganded RAR/RXR heterodimer binds to co-repressor complexes that provide a link between the heterodimer and histone deacetylases, resulting in chromatin condensation and gene silencing by removing acetyl groups from nucleosomal histones. Ligand binding to the retinoid receptors induces their conformational change, which allows the interaction between RAR/RXR and co-activators. Co-activators form multiprotein complexes that have histone acetyltransferase activity to acetylate histone N-terminal tails. Acetylation of histones leads to nucleosomal repulsion and chromatin decondensation, which is thought to be indispensable for the transcriptional activation by retinoid receptor.

We have found that malfunction of RXR{alpha} due to post-translational modification by phosphorylation is associated with carcinogenesis of HCC (8,9) in addition to depletion of hepatic retinoid (3). Phosphorylation is reported to enhance or suppress the function of nuclear receptors in a context-dependent manner. Solomon et al. (10) have shown that in ras-transfected keratinocytes phosphorylation of RXR{alpha} at serine 260 by activated Ras-extracellular signal-regulated kinase (Erk) 1/2 [also known as mitogen-activated protein (MAP) kinase] pathway results in attenuated transactivation by VDR/RXR{alpha} heterodimer and consequently in resistance to the growth inhibitory effect of 1,25-didehydroxyvitamin D3 and RXR-specific agonist. Similarly, we have also demonstrated that phosphorylation of RXR{alpha} at serine 260 by Erk 1/2 impairs RXR{alpha}s function and its normal degradation through the ubiquitin–proteasome pathway in both human HCC tissues and HuH7 human HCC cells (9,11). This leads to accumulation of non-functional phosphoRXR{alpha} in the cancer cells, which may interfere with the function of remaining normal RXR{alpha} in a dominant-negative manner, thereby rendering the cancer cells much less sensitive to 9cRA. Hence, HCC cells evade 9cRA-induced apoptosis (12). In contrast, HCC cells are sensitive to acyclic retinoid and undergo apoptosis (12). Because over-expression of phosphorylation-site mutated unphosphoRXR{alpha} restored its activity and suppressed tumor cell growth (9), we have examined whether acyclic retinoid can suppress RXR{alpha} phosphorylation and thereby restore its function in HCC cells.

We have pursued this possibility using HuH7 cells, which reveal that acyclic retinoid dephosphorylates RXR{alpha} by inactivating the Ras-Erk system in HCC cells, potentiating the responses of RXR{alpha} to physiological concentration of 9cRA. Our findings identify these events as a key molecular mechanism underlying the anti-tumor activity of acyclic retinoid.


    Materials and methods
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
Materials
Acyclic retinoid (NIK333) was supplied from Nikken Chemicals Co. (Tokyo, Japan) (3). 9cRA, lactoalbumin hydrolysate and monoclonal antibody against phosphoserine (PSR-45) were purchased from Sigma Chemical (St Louis, MO). Polyclonal anti-RXR{alpha} (DN197) and polyclonal anti-MAP kinase phosphatase-1 (MKP-1) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Polyclonal anti-Erk 1/2 antibodies and polyclonal anti-phosphoErk 1/2 antibodies were from Cell Signaling Technology (Beverly, MA). Monoclonal antibody against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was from Chemicon International (Temecula, CA). RPMI 1640 media and fetal calf serum (FCS) were from Invitrogen (Carlsbad, CA).

Cell culture and treatment
HuH7 cells were obtained from the Japanese Cancer Research Resources Bank (Tokyo, Japan) and maintained in RPMI1640 medium supplemented with 1% FCS and 0.2% lactoalbumin hydrolysate as described previously (9,11). In an in vitro culture model, FCS present in the medium at concentration >1% interferes with the growth suppression by acyclic retinoid (13). HuH7 cells were plated on 100 mm-plastic dishes (8 x 105 cells/dish) or 96-well plates (1.75 x 103 cells/well) at the cell density of 30–40% confluency and were treated for 24 h in the same medium with the indicated concentrations of retinoids dissolved in ethanol at a final concentration of 0.05%. Cell numbers were counted using Trypan Blue dye exclusion method.

Preparation of cell extracts and western blot analysis
Preparation of cell extracts and western blot analyses of total Erk 1/2, phosphoErk 1/2, MKP-1 and GAPDH were performed as described previously (9). For detection of phosphoRXR{alpha}, RXR{alpha} was affinity-purified from the cell extracts using anti-RXR{alpha} antibody-immobilized Sepharose beads, and then subjected to western blot analyses employing anti-phosphoserine antibody (9). As a control, proteins precipitated with non-immunized rabbit antibody-linked beads were analyzed. Protein concentrations in the samples were determined by Bio-Rad protein assay kit (Hercules, CA). The signals were detected with an Amersham Bioscience ECL system (Piscataway, NJ). Densitometric analysis was performed using the NIH image version 1.61 software.

Determination of Ras activity
Ras activities were determined using a Ras activation assay kit (Upstate Biotechnology, Lake Placid, NY) according to the manufacturer's instruction. This assay detects the activated Ras bound to Raf-1.

Luciferase reporter assay
A reporter plasmid, tk-CRBPII-RXRE-Luc, containing multiple copies of the DR1 type RXRE sequences within rat cellular retinol-binding protein type II (CRBPII) promoter up-stream of luciferase cDNA, was kindly provided by the late Dr K.Umesono (Kyoto University, Kyoto, Japan). Transfection with tk-CRBP-II-Luc reporter and measurement of luciferase activity of cell lysates were performed using a dual-luciferase reporter assay system (Promega, Madison, WI) as described previously (9). Cells were cotransfected with pRL-CMV (Renilla luciferase) as an internal standard to normalize transfection efficiency (14). Furthermore, to see clear differences in the transcriptional activation via RXRE, wild-type RXR{alpha} was transfected to HuH7 cells.

Transfection of mutant RXR{alpha}
Construction of a human RXR{alpha} mutant cDNA, in which serines 259 and 260 were mutated to alanine (S260A), an unphosphorylated mimic of RXR{alpha}, and its transfection to HuH7 cells were performed as described previously (9).

Statistical analysis
Data are expressed as the mean and SD. Statistical significance was assessed with one-way analysis of variance followed by Sheffe's t-test.


    Results
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
Acyclic retinoid reduced phosphoserine RXR{alpha} levels and Erk activity
In our previous study, we validated human HCC-derived HuH7 cells as a faithful representative of clinical HCC tissues in terms of MAP kinase-mediated phosphorylation of RXR{alpha} (9). Therefore, we have used HuH7 cells in the present study to examine if acyclic retinoid might prevent the phosphorylation of RXR{alpha} and restore its function. Because malfunction of RXR{alpha} is due to phosphorylation at a serine residue (9), we first examined if acyclic retinoid might dephosphorylate a phosphoserine of RXR{alpha}. As depicted in Figure 1A, levels of phosphoserine RXR{alpha} (lane 1) band was reduced markedly following treatment with acyclic retinoid alone (lane 2) and with the combination of acyclic retinoid plus 9cRA (lane 4), but not with 9cRA alone (lane 3).



View larger version (21K):
[in this window]
[in a new window]
 
Fig. 1. Effects of retinoids on the levels of phosphoserine RXR{alpha} (A) and phosphoErk 1/2 (B) in HuH7 cells. HuH7 cells were treated with vehicle (panels A and B, lanes and column 1), 1 µM acyclic retinoid (lanes and column 2), 1 µM 9cRA (lanes and column 3) or their combination (lanes and column 4) for 24 h. (A) RXR{alpha} was affinity-purified from the cell extract using anti-RXR{alpha}-antibody-immobilized Sepharose and then subjected to western blot analysis using anti-phosphoserine antibody. (B) Western blot analyses of phosphoErk 1/2 and total Erk 1/2 were performed with the respective specific antibodies using the same extract as in panel A. Relative intensity of the band was determined by densitometry (columns 1–4). Values represent the amounts of phosphoErk divided by those of total Erk (the mean ± SD, n = 5). An asterisk represents significant difference (P < 0.05) compared to columns 1 and 3.

 
We have shown previously that Erk 1/2, constitutively expressed in the HCC cells (11), plays a crucial role in RXR{alpha} phosphorylation (9). We thus examined if acyclic retinoid might suppress Erk activity. As depicted in Figure 1B, the amount of phosphoErk 1/2, active forms of Erk, was also reduced significantly (P < 0.05) following treatment with acyclic retinoid alone (lanes and column 2) and with the combination of acyclic retinoid plus 9cRA (lanes and column 4), but not with 9cRA alone (lanes and column 3), as has been reported previously (11). The amount of total Erk 1/2 was not affected by either treatment (Figure 1B). These results suggest that HuH7 cells are refractory to 9cRA, but sensitive to acyclic retinoid, in regulating the activation of Erk 1/2 and subsequent RXR{alpha} phosphorylation.

Differential regulation of Ras and MKP-1 levels between acyclic retinoid and 9cRA
Our previous work suggested that the down-regulation of transforming growth factor (TGF-{alpha}) interrupted autocrine growth signals via the epidermal growth factor (EGF) receptor, the receptor for TGF-{alpha}, providing a potential mechanism for apoptosis induction by acyclic retinoid in HuH7 cells (15). Therefore, we examined if acyclic retinoid might downregulate the activity of Ras, a small GTP-binding protein, which mediates activation of the MAP kinase pathway following stimulation by TGF-{alpha} (16). As shown in Figure 2A, Raf-1-bound Ras activities were inhibited by 70% in acyclic retinoid-treated HuH7 cells (lane and column 2). Similar inhibition was also observed following 9cRA-treatment (Figure 2A, lane and column 3).



View larger version (17K):
[in this window]
[in a new window]
 
Fig. 2. Effects of retinoids on the levels of activated Ras (A) and MKP-1 (B) in HuH7 cells. HuH7 cells were treated with vehicle (panels A and B, lanes and columns 1), 1 µM acyclic retinoid (lanes and columns 2), 1 µM 9cRA (lanes and columns 3) or their combination (panel B, lanes and column 4) for 24 h. (A) Levels of Ras bound to Raf-1. Ras was precipitated in the cell extract using Raf-1/Ras-binding domain-immobilized agarose and then subjected to western blot analysis using anti-Ras antibody. (B) Western blot analyses of MKP-1 and GAPDH were performed with the respective specific antibodies using the same extract as in panel A. (A) Relative intensity of the band was determined by densitometry (columns 1–3). Values are the mean ± SD (n = 5). Double asterisks represent significant difference (P < 0.01) compared to column 1. (B) Values represent the amounts of MKP-1 divided by those of GAPDH (the mean ± SD, n = 5). An asterisk represents significant difference (P < 0.05) compared with columns 1, 2 and 4.

 
To provide an explanation for the discrepancy between 9cRA's effects on Ras activity (suppressed; Figure 2A, lane and column 3) and on phosphoErk levels (unchanged; Figure 1B, lanes and column 3), we analyzed the effect of 9cRA on the levels of MKP-1, a phosphatase that inactivates Erk 1/2. As depicted in Figure 2B, 9cRA suppressed MKP-1 levels by 40% (lanes and column 3), whereas acyclic retinoid did not reduce the levels of MKP-1 either in the absence (lanes and column 2) or in the presence of 9cRA (lanes and column 4). These results suggest that because 9cRA suppresses simultaneously both activating protein (Ras) and inactivating enzyme (MKP-1), 9cRA leaves the levels of phosphoErk 1/2 unaffected. In contrast, as acyclic retinoid downregulates Ras activity without accompanying a decrease in MKP-1 levels, it suppresses phosphoErk 1/2 levels and prevents generation of phosphoRXR{alpha}.

Acyclic retinoid potentiates 9cRA-induced transactivation via RXRE
We have shown previously that compared with phosphorylated RXR{alpha}, an unphosphorylated form of RXR{alpha} exerts much higher transactivation activity in response to 9cRA (9). Acyclic retinoid at >=5 µM can serve as a ligand for RXR{alpha}, but has much less potent transactivation activity than that of 9cRA (7,17,18). Together with the results obtained in the present study, the data suggest that 9cRA cannot prevent phosphorylation of RXR{alpha}, but is a potent ligand when RXR{alpha} is kept unphosphorylated, whereas acyclic retinoid can prevent the phosphorylation, but is a weak ligand. This led us to explore whether a combination of 9cRA (a potent ligand) and acyclic retinoid (a weak ligand preventing phosphorylation) might exert a cooperativity on transactivation via RXRE. This suggestion was borne out in the findings illustrated in Figure 3.



View larger version (23K):
[in this window]
[in a new window]
 
Fig. 3. Cooperativity between 9cRA and acyclic retinoid in RXRE-mediated transactivation activity in HuH7 cells. Cells were cotransfected with CRBPII-RXRE-luciferase reporter gene, tk-CRBPII-Luc, and wild-type RXR{alpha}-expressing vector along with pRL-CMV (Renilla luciferase) as an internal standard using lipofection. Cells were then treated for 24 h with indicated concentrations of acyclic retinoid alone (curve 1), 9cRA alone (curve 2) or the combination of 1 µM acyclic retinoid plus indicated concentrations of 9cRA (curve 3). Cell lysates were prepared and luciferase activity in each cell lysate was measured and plotted as fold-induction compared with the activity of vehicle-treated cells after normalization with Renilla luciferase activity. Values are the mean ± SD (n = 5). An asterisk and a dagger represent significant differences (P < 0.05) from curves 1 and 2, respectively, at the indicated concentration.

 
HuH7 cells, which had been transfected with an RXRE-containing gene promoter, were treated with incremental concentrations of 9cRA or acyclic retinoid alone, or with a combination of incremental concentrations of 9cRA and a fixed concentration (1 µM) of acyclic retinoid, and then transactivation activity was measured. 9cRA induced transactivation in a dose-dependent manner at >=100 nM (Figure 3, curve 2). These activities were further enhanced ~20-fold by simultaneous addition of acyclic retinoid (Figure 3, curve 3), which alone had no transactivating activity (curve 1). In the previous report we found that acyclic retinoid alone induced RXRE-mediated transactivation activity (17). Although we cannot explain the reason for this discrepancy, we speculate that the differences in the experimental condition (techniques employed for transfection, culture media conditions and cell densities) would be responsible for it.

This current result suggests that there might be a 20-fold molar excess of non-functioning phosphoRXR{alpha} compared with normal RXR{alpha} in the cancer cells. Importantly, even 9cRA at physiological concentrations as low as 1–10 nM (6,19), which alone was not transactivating, became active in conjunction with 1 µM acyclic retinoid, a pharmacological concentration in patients' plasma (4). These results suggest that prevention of RXR{alpha} phosphorylation by acyclic retinoid might be linked to the restoration of its function and transactivation activity in response to physiological concentration of 9cRA in vivo.

Acyclic retinoid and 9cRA cooperatively suppress proliferation of HuH7 cells
We have suggested previously that malfunction of RXR{alpha} due to phosphorylation appears to be associated with aberrant proliferation of HuH7 cells, and that introduction of an unphosphorylated form of RXR{alpha} suppresses cell growth (9). Therefore, we examined if the combination of acyclic retinoid plus 9cRA might cooperatively suppress the growth of HuH7 cells (Figure 4). To see clearer differences in the growth suppression between single treatment with each of two retinoids and their combination, we used the culture medium containing FCS, which was known to regress the effect of acyclic retinoid (13). Acyclic retinoid alone at concentrations <=1 µM minimally suppressed cell growth (<=3%; Figure 4, curve 1) as we have reported previously (12). 9cRA was not effective until 100 nM, and slightly suppressed the growth at 1 µM, culminating in a 23% inhibition (Figure 4, curve 2). In contrast, in conjunction with 1 µM acyclic retinoid, 9cRA suppressed cell growth from 0.1 nM and resulted in 25% inhibition at 10 nM (Figure 4, curve 4). Growth suppression by 9cRA was also restored when HuH7 cells were transfected with unphosphorylated mimic of RXR{alpha} (S260A mutant; Figure 4, curve 3). These results suggest that prevention of phosphorylation of RXR{alpha} and thus restoration of its function by acyclic retinoid enhance the susceptibility of cancer cells to 9cRA, enabling growth suppression at physiological concentrations. This mechanism may provide a potential explanation for inhibition of the development of HCC by acyclic retinoid in vivo, although other possibilities remain.



View larger version (28K):
[in this window]
[in a new window]
 
Fig. 4. Cooperativity between 9cRA and acyclic retinoid in growth suppression of HuH7 cells. After cells were cultured in 96-well plates and treated for 24 h with indicated concentrations of acyclic retinoid alone (curve 1), 9cRA alone (curve 2) or the combination of 1 µM acyclic retinoid plus indicated concentrations of 9cRA (curve 4), cell number was counted by Trypan Blue dye exclusion method. Some cells were transfected with a mutant (S260A) RXR{alpha} cDNA-expressing plasmid vector and then treated with indicated concentrations of 9cRA for 24 h (curve 3). Values are the mean ± SD (n = 5). An asterisk represents significant differences (P < 0.05) from curves 1 and 2 at the indicated concentration.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
We here demonstrate a novel action of a synthetic retinoid, acyclic retinoid, to prevent phosphorylation of RXR{alpha} (Figure 1A) by inhibiting the activities of Ras-Raf-Erk 1/2 system (Figures 1B and 2A), and thereby to restore the function of RXR{alpha} in HCC cells (Figure 3) in addition to its previously established function as an RXR-ligand (7). 9cRA, a natural RXR{alpha}-ligand, failed to suppress the RXR{alpha} phosphorylation (Figure 1A), probably because 9cRA inhibited both activated Ras (activating protein of Erk) and MKP-1 (inactivating enzyme of Erk) (Figure 2) at the same time, thereby leaving the Erk 1/2 activity unchanged (Figure 1B). Growth suppression by 9cRA was restored when HuH7 cells were either co-treated with acyclic retinoid or transfected with unphosphorylated mimic of RXR{alpha} (S260A RXR{alpha}; Figure 4). Thus, the dephosphorylating ability of acyclic retinoid may play a key role in its growth inhibitory effect on HCC (Figure 5). The concentration of the respective retinoid used in the present study (1 µM for acyclic retinoid and 10 nM for 9cRA) is within the physiological ranges (4,6,19), implying that acyclic retinoid and 9cRA may work cooperatively in vivo in the liver.



View larger version (21K):
[in this window]
[in a new window]
 
Fig. 5. Schematic representation of the effect of acyclic retinoid on RXR{alpha} phosphorylation in HCC cells and its implication for specific antitumor activity of the retinoid. In normal hepatocytes, 9cRA binds to RXR{alpha} and transactivates downstream genes via RXRE that may regulate cell proliferation (1). In HCC cells, Ras/MAP kinase pathway is highly activated (2) and phosphorylates RXR{alpha} at serine residue (3), impairing functions of the receptor. Acyclic retinoid suppresses Ras/MAP kinase sequence, dephosphorylates RXR{alpha}, restores the function of the receptor, and subsequently inhibits the cancer cell growth (4). Acyclic retinoid might inhibit Ras-Erk 1/2 system independently of RXR{alpha} (4).

 
Retinoid receptors have anticancer properties (1,6) and loss of the receptors is largely involved in the carcinogenic process of various types of cancers (2025). In particular, recent studies indicate that RXR{alpha} is required for apoptosis-induction and/or growth suppression of cancer cells via an autonomous RXR pathway (26,27) or by heterodimerization with other nuclear receptors (10,28). Thus, restoration of impaired RXR{alpha} activity may provide a key strategy to render HCC cells sensitive to RA and thus prevent cancer development (29). Solomon et al. originally suggested a similar strategy to use an Erk inhibitor (e.g. PD98059) to prevent phosphorylation of RXR{alpha} and restore its function as well as consequent vitamin D signaling via VDR/RXR{alpha} heterodimer, thereby reversing the resistance of cancer cells to 1,25-dihydroxyvitamin D3 (30). The novel activities of acyclic retinoid as an Erk inhibitor may provide a clue in uncovering the mechanism of its specific antitumor activity against HCC. Although the ligand activity of acyclic retinoid is much weaker than that of 9cRA (Figure 3), the retinoid might work cooperatively with endogenous 9cRA in vivo and thereby suppress the growth of the tumor whose RXR{alpha} is phosphorylated. We have found recently that potential downstream genes inhibiting the cancer cell growth include STAT1 (31) and p21 (18).

The detailed molecular mechanism by which acyclic retinoid suppresses RXR{alpha} phosphorylation remains to be elucidated. Others have reported a similar effect of atRA in inhibiting Erk 1/2 activation induced by pro-angiogenic agents in the endothelial cells; however, the molecular mechanisms also remain obscure (32). Recently, Sah et al. (33) have reported that an RAR-selective retinoid inhibits EGF-induced Erk 1/2 activation and subsequent cell proliferation in a human uterine cervical cell line. In that study the retinoid seemed to act in an RAR-dependent manner because the effect is reversed by co-treatment with an RAR antagonist (33). In contrast, in the present study acyclic retinoid suppressed Erk activities even in HCC cells in which RXR{alpha} function is impaired, suggesting the possibility of RXR{alpha}-independent mechanism. In fact, our preliminary data suggest that the inhibitory effect of acyclic retinoid on Erk does not require de novo protein synthesis (Matsushima-Nishiwaki et al., unpublished observation), suggesting a dispensability of retinoid receptor-mediated transactivation, which often accompanies autoinduction of the receptors (20,22,25). Thus, acyclic retinoid might exert its antitumor activity independently of nuclear receptors, as has been reported with other synthetic retinoids including 4-hydroxyphenyl retinamide (4HPR) and CD437 (3440). Our previous study demonstrated that acyclic retinoid downregulates TGF-{alpha} expression in HuH7 cells, and that inclusion with TGF-{alpha} prevents acyclic retinoid-induced apoptosis in the cells (15). Because TGF-{alpha} is a ligand for EGF receptor, acyclic retinoid may directly interfere with the signal transducing sequence of TGF-{alpha}-EGF receptor-Ras-Raf-Erk system.

Phosphorylation has recently been shown to modulate the function of many nuclear receptors. The effect of phosphorylation on the function of each receptor is distinct depending upon the type of the receptor and/or kinases involved as well as upon the sites of phosphorylation. Phosphorylation of RXR{alpha} at Tyr249 by MAP kinase kinase-4 and by its downstream mediator c-Jun N-terminal kinase (JNK) has been reported, which results in the reduced transactivation via RAR/RXR complex (41). In contrast, others have reported that RXR{alpha} phosphorylation by JNK does not affect the transactivating properties of either RXR{alpha} homodimer or RXR{alpha}/RAR{alpha} heterodimer (42). On the other hand, phosphorylation of RAR seems to enhance its transcriptional activities, irrespective of RAR subtypes and types of kinases (4345). Much like RXR/RAR, controversy persists regarding the phosphorylation of PPAR, depending upon the experimental conditions (4648). It is intriguing to see if acyclic retinoids affect phosphorylation of other nuclear receptors and their biological activities.

HCC has become one of the most frequent cancers in the world (49). HCC arises in patients with chronic viral hepatitis and cirrhosis at a high rate (3–5% annually) and is a major cause of morbidity and mortality in patients with advanced liver disease. Thus, prevention of HCC by targeting such a high-risk group is of great significance. We have successfully prevented the development of HCC with the use of acyclic retinoid in a clinical trial (4,5). In that study, we proposed a concept of ‘clonal deletion’ therapy, in which the retinoid eradicates occult malignant cell clones under the detection limit of diagnostic images by inducing apoptosis (50). The present study may suggest a specific molecular mechanism by which acyclic retinoid renders HCC cell clones susceptible to the retinoid therapy and thereby removes the invisible cancer cells.


    Acknowledgments
 
This study was supported partly by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan (12670472 to M.O., 13670579 to S.K. and 10557055 to H.M.), the Nagono Memorial Foundation (to M.O.), the Liver Forum in Kyoto (to M.O.), and the NIDDK (RO1DK 37340 to S.L.F.). The authors thank Dr Y.Muto (Sugiyama Jogakuen University) for the critical reading of the manuscript.


    References
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 

  1. Hansen,L.A., Sigman,C.C., Andreola,F., Ross,S.A., Kelloff,G.J. and De Luca,L.M. (2000) Retinoids in chemoprevention and differentiation therapy. Carcinogenesis, 21, 1271–1279.[Abstract/Free Full Text]
  2. Moon,R.C., Mehta,R.G. and Rao,K.V.N. (1994) Retinoids and cancer in experimental animals. In Sporn,M.B., Roberts,A.B. and Goodman,D.S. (eds), The Retinoids: Biology, Chemistry and Medicine, 2nd Edn. Raven Press, New York, pp. 573–595.
  3. Muto,Y. and Moriwaki,H. (1984) Antitumor activity of vitamin A and its derivatives. J. Natl Cancer Inst., 73, 1389–1393.[ISI][Medline]
  4. Muto,Y., Moriwaki,H., Ninomiya,M. et al. (1996) Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N. Engl. J. Med., 334, 1561–1567.[Abstract/Free Full Text]
  5. Muto,Y., Moriwaki,H. and Saito,A. (1999) Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N. Engl. J. Med., 340, 1046–1047.[Free Full Text]
  6. Mangelsdorf,D.J., Umesono,K. and Evans,R.M. (1994) The retinoid receptors. In Sporn,M.B., Roberts,A.B. and Goodman,D.S. (eds), The Retinoids: Biology, Chemistry and Medicine, 2nd Edn. Raven Press, New York, pp. 319–349.
  7. Altucci,L. and Gronemeyer,H. (2001) The promise of retinoids to fight against cancer. Nature Rev. Cancer, 1, 181–193.[CrossRef][Medline]
  8. Matsushima-Nishiwaki,R., Shidoji,Y., Nishiwaki,S., Yamada,T., Moriwaki,H. and Muto,Y. (1996) Aberrant metabolism of retinoid X receptor proteins in human hepatocellular carcinoma. Mol. Cell. Endocrinol., 121, 179–190.[CrossRef][ISI][Medline]
  9. Matsushima-Nishiwaki,R., Okuno,M., Adachi,S., Sano,T., Akita,K., Moriwaki,H., Friedman,S.L. and Kojima,S. (2001) Phosphorylation of retinoid X receptor {alpha} at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res., 61, 7675–7682.[Abstract/Free Full Text]
  10. Solomon,C., White,J.H. and Kremer,R. (1999) Mitogen-activated protein kinase inhibits 1,25-dihydroxyvitamin D3-dependent signal transduction by phosphorylating human retinoid X receptor {alpha}. J. Clin. Invest., 103, 1729–1735.[Abstract/Free Full Text]
  11. Adachi,S., Okuno,M., Matsushima-Nishiwaki,R., Takano,Y., Kojima,S., Friedman,S.L., Moriwaki,H. and Okano,Y. (2002) Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma. Hepatology, 35, 332–340.[CrossRef][ISI][Medline]
  12. Yasuda,I., Shiratori,Y., Adachi,S., Obora,A., Takemura,M., Okuno,M., Shidoji,Y., Seishima,M., Muto,Y. and Moriwaki,H. (2002) Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. J. Hepatol., 36, 660–671.[CrossRef][ISI][Medline]
  13. Nakamura,N., Shidoji,Y., Yamada,Y., Hatakeyama,H., Moriwaki,H. and Muto,Y. (1995) Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7. Biochem. Biophys. Res. Commun., 207, 382–388.[CrossRef][ISI][Medline]
  14. Suzuki,Y., Shimada,J., Shudo,K., Matsumura,M., Crippa,M.P. and Kojima,S. (1999) Physical interaction between retinoic acid receptor and Sp1: mechanism for induction of urokinase by retinoic acid. Blood, 93, 4264–4276.[Abstract/Free Full Text]
  15. Nakamura,N., Shidoji,Y., Moriwaki,H. and Muto,Y. (1996) Apoptosis in human hepatoma cell line induced by 4,5-didehydrogeranylgeranoic acid (acyclic retinoid) via down-regulation of transforming growth factor-{alpha}. Biochem. Biophys. Res. Commun., 219, 100–104.[CrossRef][ISI][Medline]
  16. Seufferlein,T., Van Lint,J., Liptay,S., Adler,G. and Schmid,R.M. (1999) Transforming growth factor alpha activates Ha-Ras in human pancreatic cancer cells with Ki-ras mutations. Gastroenterology, 116, 1441–1452.[ISI][Medline]
  17. Araki,H., Shidoji,Y., Yamada,Y., Moriwaki,H. and Muto,Y. (1995) Retinoid agonist activities of synthetic geranyl geranoic acid derivatives. Biochem. Biophys. Res. Commun., 209, 66–72.[CrossRef][ISI][Medline]
  18. Suzui,M., Masuda,M., Lim,J.T.E., Albanese,C., Pestell,R.G. and Weinstein,I.B. (2002) Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21CIP1 and inhibition of expression of cyclic D1. Cancer Res., 62, 3997–4006.[Abstract/Free Full Text]
  19. Arnhold,T., Tzimas,G., Wittfoht,W., Plonait,S. and Nau,H. (1996) Identification of 9-cis-retinoic acid, 9,13-di-cis-retinoic acid and 14-hydroxy-4,14-retro-retinol in human plasma after liver consumption. Life Sci., 59, PL 169–177.[CrossRef][ISI][Medline]
  20. Lotan,R., Xu,X.C., Lippman,S.M., Ro,J.Y., Lee,J.S., Lee,J.J. and Hong,W.K. (1995) Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N. Engl. J. Med., 332, 1405–1410.[Abstract/Free Full Text]
  21. Berard,J., Laboune,F., Mukuna,M., Masse,S., Kothary,R. and Bradley,W.E. (1996) Lung tumors in mice expressing an antisense RARbeta2 transgene. FASEB J., 10, 1091–1097.[Abstract/Free Full Text]
  22. Geisen,C., Denk,C., Gremm,B., Baust,C., Karger,A., Bollag,W. and Schwarz,E. (1997) High-level expression of the retinoic acid receptor beta gene in normal cells of the uterine cervix is regulated by the retinoic acid receptor alpha and is abnormally down-regulated in cervical carcinoma cells. Cancer Res., 57, 1460–1467.[Abstract]
  23. Xu,X.C., Sneige,N., Liu,X., Nandagiri,R., Lee,J.J., Lukmanji,F., Hortobagyi,G., Lippman,S.M., Dhingra,K. and Lotan,R. (1997) Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis. Cancer Res., 57, 4992–4996.[Abstract]
  24. Xu,X.C., Sozzi,G., Lee,J.S., Lee,J.J., Pastorino,U., Pilotti,S., Kurie,J.M., Hong,W.K. and Lotan,R. (1997) Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. J. Natl Cancer Inst., 89, 624–629.[Abstract/Free Full Text]
  25. Xu,X.C., Liu,X., Tahara,E., Lippman,S.M. and Lotan,R. (1999) Expression and up-regulation of retinoic acid receptor-beta is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines. Cancer Res., 59, 2477–2483.[Abstract/Free Full Text]
  26. Benoit,G.R., Flexor,M., Besançon,F. et al. (2001) Autonomous rexinoid death signaling is suppressed by converging signaling pathways in immature leukemia cells. Mol. Endocrinol., 15, 1154–1169.[Abstract/Free Full Text]
  27. Rochtte-Egly,C. and Chambon,P. (2001) F9 embryocarcinoma cells: a cell autonomous model to study the functional selectivity of RARs and RXRs in retinoid signaling. Histol. Histopathol., 16, 909–922.[ISI][Medline]
  28. Nagy,L., Thomazy,V.A., Heyman,R.A. and Davies,P.J.A. (1998) Retinoid-induced apoptosis in normal and neoplastic tissues. Cell Death Differ., 5, 11–19.[CrossRef][ISI][Medline]
  29. Okuno,M., Sano,T., Matsuhima-Nishiwaki,R., Adachi,S., Akita,K., Okano,Y., Kojima,S. and Moriwaki,H. (2001) Apoptosis induction by acyclic retinoid: a molecular basis of ‘clonal deletion’ therapy for hepatocellular carcinoma. Jpn. J. Clin. Oncol., 31, 359–362.[Abstract/Free Full Text]
  30. Solomon,C., White,J.H., Rhim,J.S. and Kremer,R. (2001) Vitamin D resistance in RAS-transformed keratinocytes: mechanism and reversal strategies. Radiat. Res., 155, 156–162.[ISI][Medline]
  31. Obora,A., Shiratori,Y., Okuno,M. et al. (2002) Synergistic induction of apoptosis by acyclic retinoid and interferon-ß in human hepatocellular carcinoma cells. Hepatology, 36, 1115–1124.[CrossRef][ISI][Medline]
  32. González,M.V., González-Sancho,J.M., Caelles,C., Munoz,A. and Jiménez,B. (1999) Hormone-activated nuclear receptors inhibit the stimulation of the JNK and ERK signalling pathways in endothelial cells. FEBS Lett., 459, 272–276.[CrossRef][ISI][Medline]
  33. Sah,J.F., Eckert,R.L., Chandraratna,R.A.S. and Rorke,E.A. (2002) Retinoids suppress epidermal growth factor-associated cell proliferation by inhibiting epidermal growth factor receptor-dependent ERK1/2 activation. J. Biol. Chem., 277, 9728–9735.[Abstract/Free Full Text]
  34. Sheikh,M.S., Shao,Z.-M., Li,X.-S. et al. (1995) N-(4-hydroxyphenyl)-retinamide induces (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis, 16, 2477–2486.[Abstract]
  35. Sani,B.P., Shealy,Y.F. and Hill,D.L. (1995) N-(4-Hydroxyphenyl) retinamide interactions with retinoid-binding proteins/receptors. Carcinogenesis, 16, 2531–2534.[Abstract]
  36. Oridate,N., Lotan,D., Xu,X.C., Hong,W.K. and Lotan,R. (1996) Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. Clin. Cancer Res., 2, 855–863.[Abstract]
  37. Hsu,C.A., Rishi,A.K., Li,X.-S., Gerald,T.M., Dawson,M.I., Schiffer,C., Reichert,U., Shroot,B., Porier,G.C. and Fontana,J.A. (1997) Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway. Blood, 89, 4470–4479.[Abstract/Free Full Text]
  38. Sun,S.-Y., Yue,P., Shroot,B., Hong,W.K. and Lotan,R. (1997) Induction of apoptosis in human non-small cell lung carcinoma cells by the novel synthetic retinoid CD437. J. Cell. Physiol., 173, 279–284.[CrossRef][ISI][Medline]
  39. Clifford,J.L., Menter,D.G., Wang,M., Lotan,R. and Lippman,S.M. (1999) Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res., 59, 14–18.[Abstract/Free Full Text]
  40. Sun,S.-Y., Yue,P., Chandraratna,R.A.S., Tesfaigzi,Y., Hong,W.K. and Lotan,R. (2000) Dual mechanisms of action of the retinoid CD437: nuclear retinoic acid receptor-mediated suppression of squamous differentiation and receptor-independent induction of apoptosis in UMSCC22B human head and neck squamous cell carcinoma cells. Mol. Pharmacol., 58, 508–514.[Abstract/Free Full Text]
  41. Lee,H.-Y., Suh,Y.-A., Robinson,M.J., Clifford,J.L., Hong,W.K., Woodgett,J.R., Cobb,M.H., Mangelsdorf,D.J. and Kurie,J.M. (2000) Stress pathway activation induces phosphorylation of retinoid X receptor. J. Biol. Chem., 275, 32193–32199.[Abstract/Free Full Text]
  42. Adam-Stitah,S., Penna,L., Chambon,P. and Rochette-Egly,C. (1999) Hyperphosphorylation of the retinoid X receptor {alpha} by activated c-Jun NH2-terminal kinases. J. Biol. Chem., 274, 18932–18941.[Abstract/Free Full Text]
  43. Rochette-Egly,C., Adam,S., Rossignol,M., Egly,J.M. and Chambon,P. (1997) Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7. Cell, 90, 97–107.[ISI][Medline]
  44. Gianní,M., Kopf,E., Bastien,J., Oulad-Abdelghani,M., Garattini,E., Chambon,P. and Rochette-Egly,C. (2002) Down-regulation of the phosphatidylinositol 3-kinase/Akt pathway is involved in retinoic acid-induced phosphorylation, degradation and transcriptional activity of retinoic acid receptor {gamma}2. J. Biol. Chem., 277, 24859–24862.[Abstract/Free Full Text]
  45. Boskovic,G., Desai,D. and Niles,R.M. (2002) Regulation of retinoic acid receptor {alpha} by protein kinase C in B16 mouse melanoma cells. J. Biol. Chem., 277, 26113–26119.[Abstract/Free Full Text]
  46. Shao,D., Rangwala,S.M., Bailey,S.T., Krakow,S.L., Reginato,M.J. and Lazar,M.A. (1998) Interdomain communication regulating ligand binding by PPAR-{gamma}. Nature, 396, 377–380.[CrossRef][ISI][Medline]
  47. Zhang,B., Berger,J., Zhou,G., Elbrecht,A., Biswas,S., White-Carrington,S., Szalkowski,D. and Moller,D.E. (1996) Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor {gamma}. J. Biol. Chem., 271, 31771–31774.[Abstract/Free Full Text]
  48. Hsi,L.C., Wilson,L., Nixon,J. and Eling,T.E. (2001) 15-Lipoxygenase-1 metabolites down-regulate peroxisome proliferator-activated receptor {gamma} via the MAPK signaling pathway. J Biol. Chem., 276, 34545–34552.[Abstract/Free Full Text]
  49. Okuno,M., Kojima,S. and Moriwaki,H. (2001) Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives. J. Gastroenterol. Hepatol., 16, 1329–1335.[CrossRef][ISI][Medline]
  50. Moriwaki,M., Yasuda,I., Shiratori,Y., Uematsu,T., Okuno,M. and Muto,Y. (1997) Deletion of serum lectin-reactive {alpha}-fetoprotein by acyclic retinoid: a potent biomarker in the chemoprevention of second primary hepatoma. Clin. Cancer Res., 3, 727–731.[Abstract]
Received August 21, 2002; revised April 4, 2003; accepted April 9, 2003.